Compare MCS & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCS | SLBT |
|---|---|---|
| Founded | 1935 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | 20 |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 853.4M | 942.1M |
| IPO Year | 1994 | 2025 |
| Metric | MCS | SLBT |
|---|---|---|
| Price | $28.10 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.33 | N/A |
| AVG Volume (30 Days) | ★ 174.1K | 79.0K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $758,458,000.00 | N/A |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | $3.15 | N/A |
| P/E Ratio | $36.70 | ★ N/A |
| Revenue Growth | ★ 3.11 | N/A |
| 52 Week Low | $12.85 | $1.50 |
| 52 Week High | $32.42 | $6.25 |
| Indicator | MCS | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 26.81 |
| Support Level | $26.52 | N/A |
| Resistance Level | $31.15 | $3.36 |
| Average True Range (ATR) | 0.63 | 0.22 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 91.81 | 9.21 |
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.